Intermittent schedules of the oral RAF–MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study

CH5126766 (also known as VS-6766, and previously named RO5126766), a novel MEK-pan-RAF inhibitor, has shown antitumour activity across various solid tumours; however, its initial development was limited by toxicity. We aimed to investigate the safety and toxicity profile of intermittent dosing sched...
Ausführliche Beschreibung

Gespeichert in:
Autor*in:

Guo, Christina [verfasserIn]

Chénard-Poirier, Maxime

Roda, Desamparados

de Miguel, Maria

Harris, Samuel J

Candilejo, Irene Moreno

Sriskandarajah, Priya

Xu, Wen

Scaranti, Mariana

Constantinidou, Anastasia

King, Jenny

Parmar, Mona

Turner, Alison J

Carreira, Suzanne

Riisnaes, Ruth

Finneran, Laura

Hall, Emma

Ishikawa, Yuji

Nakai, Kiyohiko

Tunariu, Nina

Basu, Bristi

Kaiser, Martin

Lopez, Juanita Suzanne

Minchom, Anna

de Bono, Johann S

Banerji, Udai

Format:

E-Artikel

Sprache:

Englisch

Erschienen:

2020

Umfang:

11

Übergeordnetes Werk:

Enthalten in: My - Citovsky, Vitaly ELSEVIER, 2019, London

Übergeordnetes Werk:

volume:21 ; year:2020 ; number:11 ; pages:1478-1488 ; extent:11

Links:

Volltext

DOI / URN:

10.1016/S1470-2045(20)30464-2

Katalog-ID:

ELV051917106

Nicht das Richtige dabei?

Schreiben Sie uns!